Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The current leadership team at Assembly Biosciences has a wealth of experience in the life sciences industry, with a focus on human resources and organization development. The team members have worked at various life sciences organizations in these capacities, and have also served as a senior consultant for many years. In addition, the team members have also received their education from the University of San Francisco in Human Resources and Organization Development.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Assembly Biosciences

Board of Directors

CEO and Executive Team